- ECONOMIC IMPACT -

Latest update: 22 November 

After months of decline, GDP estimates for many countries have turned positive. Consensus forecast for world GDP growth in 2021 is 6.0%.

V-shaped economic recovery is expected in most G20 nations in 2021 as vaccinations are rolled out across economies coupled with easing of restrictions.

4.22%

A movement towards decentralised trials with remote patient monitoring and site initiation are the top mitigation strategies for addressing clinical trials disruptions due to Covid-19. At the end of 3Q, 4.22% trials now have a virtual component.

60%

Just under 60% of Americans are fully vaccinated against Covid-19. Among the top ten infected countries, the US had the second highest rate of total confirmed cases in the past month.

Global economy to revive in 2021 due to mass vaccine rollout

- SECTOR IMPACT: PHARMA -

Latest update: 30 November

industry development

1,079

Trial disruption continues to level off. While 1,079 clinical trials are still disrupted, this is following a downward trend since mid-2020 has plateaued in the recent months.

301

Covid-19 has led to an increase in demand for virtual trial experience, with 301 jobs in that domain being posted in the 3Q as per GlobalData’s job analytics database.

Digitising clinical trials

The Covid-19 pandemic has triggered digital transformation in the form of an acceleration of technology-related industry trends — for example, increased use of social media and telemedicine.


As these technologies continue to become more sophisticated and both service providers and recipients become accustomed to new norms, these trends are set to continue to grow even after the pandemic subsides.


While healthcare provision has been historically viewed as an in-person experience where the patient is examined by a healthcare professional in order to receive a diagnosis for any health issues, Covid-19 revolutionised the perception of patient care, with telemedicine becoming a standard in the clinical workflow.

Key trends due to Covid-19

Share this article

Go to article: Home | Improving safety for multiple drug regimes Go to article: In this issueGo to article: ContentsGo to article: Curtis Health CapsGo to article: Astrix Go to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Owen Mumford Company Insight Go to article: Owen MumfordGo to article: CommentGo to article: Use of AI in the fight against Covid-19 shows mixed results Go to article: What does Ireland’s tax hike mean for pharma?Go to article: Chinese review designations lag behind US and EUGo to article: The business benefits of text mining in life sciencesGo to article: Mettler ToledoGo to article: HOF SonderanlagenbauGo to article: In DepthGo to article: Narrow FDA panel vote on Merck’s molnupiravir bolsters outlook on mAbsGo to article: The challenges of multiple drugs safety reportingGo to article: 3D printing in drug manufacturing: unlocking future possibilitiesGo to article: Can drug repurposing uncover better treatments for UTIs?Go to article: Pfizer and Takeda deals put a spotlight on value-based pricing Go to article: Lethal injection: can pharma kill the death penalty?Go to article: Mimotopes Company Insight Go to article: MimotopesGo to article: In DataGo to article: Middle-income countries’ healthcare sectors to keep rising through to 2024Go to article: Data analytics hiring levels in clinical trial operations rose in OctoberGo to article: Industrial automation innovation in pharma rebounded in the last quarterGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: YearbookGo to article: SHL MedicalGo to article: Dr. Paul Lohmann Company Insight Go to article: Dr. Paul LohmannGo to article: Novo NordiskGo to article: NiproGo to article: EventsGo to article: Next issue